B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PIK3C2B

MOLECULAR TARGET

phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta

UniProt: O00750NCBI Gene: 528718 compounds

PIK3C2B (phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta) is targeted by 18 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PIK3C2B

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1ly 2940024.84126
2lapatinib4.84126
3dactolisib4.2569
4pi 1034.1764
5midostaurin3.8546
6zstk 4743.5634
7buparlisib3.4029
8lestaurtinib3.0420
9apitolisib2.7114
10gedatolisib2.5612
11gsk 4613642.4010
12torin12.4010
13bimiralisib2.309
14pictilisib2.208
15tg100 1152.087
16gsk 26367712.087
17ly2940021.795
18torin 11.102

About PIK3C2B as a Drug Target

PIK3C2B (phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 18 compounds with documented PIK3C2B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PIK3C2B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.